Benitec registers $70 million of stock for initial public sale of ADSs

Bookrunner BMO, lead manager Maxim and co-manager Roth Capital assist

By Devika Patel

Knoxville, Tenn., June 22 – Benitec Biopharma Ltd. will price its initial public offering of American Depositary Shares with a 30-day greenshoe option, according to a Form F-1 filed Monday with the Securities and Exchange Commission. The company has registered up to $70 million of underlying ordinary stock.

Each ADS represents 20 ordinary shares.

BMO Capital Markets Corp. is the bookrunner. Maxim Group LLC is the lead manager, and Roth Capital Partners, LLC is the co-manager.

Proceeds will be used for clinical trials, development, preclinical studies, working capital, research and general corporate purposes.

The biotechnology company is headquartered in Balmain, New South Wales, Australia. The company has applied to list the ADSs on the Nasdaq under the symbol “BNTC.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.